In announcing the deal Embark cited a novel target that suppresses appetite increases energy expenditure and enhances insulin sensitivity In previous disclosures Embark said it had identified a peptide drug for cardiovascular and metabolic disease and a small molecule energy expenditure activator that it was investigating for obesity